Enpr-EMA workshop on 16 May 2017 opens for registration

The European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) will hold its ninth annual workshop on 16 May 2017 in London, UK. The aim of the workshop, that will take place at the premises of the European Medicines Agency (EMA), is to bring relevant stakeholders together to discuss requirements, barriers and opportunities for high-quality clinical studies in children.

Among the highlights of this year’s workshop are the recent efforts to increase cooperation between the European Union and the United States to facilitate global paediatric trials and medicine developments. Further information can be found in the workshop agenda published today.

The first day of the workshop will be open to all stakeholders including patients/parents organisations, regulators, Enpr-EMA network representatives, academia, clinical investigators and representatives from the pharmaceutical industry for paediatric studies.

Participants will hear about Enpr-EMA’s activities to foster high-quality research in paediatric medicine and will be invited to share their views on the achievements made so far and the way forward.

Registration for the first day of the workshop is open until 28 April 2017. The completed registration form should be sent to enprema@ema.europa.eu.

The second day of the workshop is reserved for discussions among the members of Enpr-EMA and the Enpr-EMA coordinating group. The coordinating group will define priorities for 2017-2018 based on the feedback received from stakeholders.

Enpr-EMA was set up to facilitate the conduct of clinical studies in children. It is an umbrella network of 39 national and international networks recognised for their experience in paediatric research. It acts as a platform for sharing good practices. Coordinated by EMA, its actions focus on:

  • fostering high-quality, ethical research on the quality, safety and efficacy of medicines for use in children;
  • helping with the recruitment of patients for clinical trials;
  • enabling collaboration between networks and medicine developers;
  • avoiding unnecessary duplication of studies;
  • promoting the European Commission framework programme for research.

Information about Enpr-EMA members is available in a fully searchable databaseExternal link icon.

Posted on the EMA website on 9 February 2017